Nippon Shinyaku : Ending March 2023(FY2022)Presentation Material for IR Meeting (Script＋Q&A (Summary)
May 23, 2023
Share
Outline of Consolidated Financial Results
for the Year Ended March 31, 2023
May 15, 2023
NIPPON SHINYAKU CO., LTD.
FY2022 Summary
Revenue
Operating profit
Profit before tax
Profit attributable
to owners of parent
144,175 million yen （ + 4.9% ）
30,049 million yen （ - 8.8% ）
30,489 million yen （ - 8.4% ）
22,812 million yen （ - 8.7% ）
Revenue
Operating profit
Profit before tax
Profit attributable to owners of parent
（Million yen）
2
Segmental Review - Pharmaceuticals -
120,650
Revenues from the licensing
of industrial property rights
+3,245
-2,493
+585
121,988
+1,337
（Million yen）
FY2021
FY2022
YoY Change
Results
Ratio
Results
Ratio
Amt
%
Ethical drugs
78,508
65.1%
81,753
67.0%
+3,245
+4.1%
Revenues from the licensing of
33,207
27.5%
30,714
25.2%
-2,493
-7.5%
industrial property rights
Profit in co-promotion
8,934
7.4%
9,520
7.8%
+585
+6.6%
Revenue
120,650
100.0%
121,988
100.0%
+1,337
+1.1%
Despite the effect of price revision by MHLW* and backlash from the loss of sales revenue from the
priority review voucher, Revenue of consolidated pharmaceuticals segment increased by 1.1% due
to increase of sales of Ethical drugs such as "Uptravi" and "Viltepso", and royalty revenue from
Uptravi's overseas sales.
*MHLW : Ministry of Health, Labour and Welfare 3
Segmental Review - Functional Food -
16,834
+4,542
+114
+32
+663
22,187
+5,352
（Million yen）
FY2021
FY2022
YoY Change
Results
Ratio
Results
Ratio
Amt
%
Protein preparations
10,841
64.4%
15,383
69.3%
+4,542
+41.9%
Preservatives
2,790
16.6%
2,905
13.1%
+114
+4.1%
Health food ingredients
1,085
6.4%
1,118
5.0%
+32
+3.0%
Others
2,116
12.6%
2,779
12.6%
+663
+31.3%
Revenue
16,834
100.0%
22,187
100.0%
+5,352
+31.8%
Revenue of consolidated functional food segment increased by 31.8% mostly due to
increase of demand from lowering COVID-19 cases and price revisions to offset price
hikes of raw materials.
4
Operating profit
32,948
+6,690
-5,789
-2,638
-1,271
+335
-224
30,049
-2,898
（Million yen）
FY2021
FY2022
YoY Change
Results
Ratio
Results
Ratio
Amt
%
Revenue
137,484
100.0%
144,175
100.0%
+6,690
+4.9%
(Pharmaceuticals)
(120,650)
(87.8%)
(121,988)
(84.6%)
(+1,337)
(+1.1%)
(Functional Food)
(16,834)
(12.2%)
(22,187)
(15.4%)
(+5,352)
(+31.8%)
Cost of sales
50,191
36.5%
55,980
38.8%
+5,789
+11.5%
SG&A expenses
32,173
23.4%
34,812
24.1%
+2,638
+8.2%
R&D expenses
22,863
16.6%
24,135
16.7%
+1,271
+5.6%
Other income
1,573
1.1%
1,908
1.3%
+335
+21.3%
Other expenses
882
0.6%
1,106
0.9%
+224
+25.4%
Operating profit
32,948
24.0%
30,049
20.8%
-2,898
-8.8%
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Nippon Shinyaku Co. Ltd. published this content on 24 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 May 2023 07:37:08 UTC.
Nippon Shinyaku Co., Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceutical products and functional foodstuffs. The Company operates in two business segments. The Pharmaceutical segment is involved in the manufacture and sale of urinary system therapeutic agents, blood cancer therapeutic agents, pain, inflammation and allergic therapeutic agents, digestive system therapeutic agents, cardiovascular systems and metabolic therapeutic agents. The Functional Foodstuff segment involves in the manufacture and sale of health food materials, quality stability preservatives, protein preparation, spice and seasoning products. The Company is also involved in the business support business, non-life insurance agency business, as well as the provision of real estate leasing services.
NIPPON SHINYAKU CO., LTD. 
